Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis

C Kan, Y Zhang, F Han, Q Xu, T Ye, N Hou… - Frontiers in …, 2021 - frontiersin.org
Aims We conducted a systematic review and meta-analysis to assess various antidiabetic
agents' association with mortality in patients with type 2 diabetes (T2DM) who have …

The association between antidiabetic agents and clinical outcomes of COVID-19 patients with diabetes: a Bayesian network meta-analysis

Y Chen, X Lv, S Lin, M Arshad, M Dai - Frontiers in Endocrinology, 2022 - frontiersin.org
Aims This study aimed to assess the impact of different antidiabetic agents on individuals
with diabetes and COVID-19. Methods We searched PubMed, Web of Science, Embase …

Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis

NN Nguyen, DS Ho, HS Nguyen, DKN Ho, HY Li… - Metabolism, 2022 - Elsevier
Background Diabetes is an independent predictor of poor outcomes in patients with COVID-
19. We compared the effects of the preadmission use of antidiabetic medications on the in …

Association of glucose-lowering drugs with outcomes in patients with diabetes before hospitalization for COVID-19: a systematic review and network meta-analysis

Z Zhu, Q Zeng, Q Liu, J Wen, G Chen - JAMA network open, 2022 - jamanetwork.com
Importance Patients with COVID-19 have a high prevalence of diabetes, and diabetes and
blood glucose control are determinants of intensive care unit admission and mortality …

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

K Khunti, VR Aroda, DL Bhatt, B Bozkurt… - Diabetes, Obesity …, 2022 - Wiley Online Library
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are now seen as an integral
part of therapy in type 2 diabetes to control not only blood glucose but to improve …

Obesity, metabolic phenotypes and COVID-19

D Sanoudou, MA Hill, MJ Belanger, K Arao… - Metabolism, 2022 - Elsevier
The pandemic resulting from the acute respiratory SARS-CoV-2 infection and the associated
COVID-19 syndrome is reaching its third year and has impacted all regions of the globe. At …

Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review …

H Permana, TA Yanto, TI Hariyanto - Diabetes Research and Clinical …, 2023 - Elsevier
Aims This study aims to examine the effectiveness of using sodium glucose transporter-2
inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients …

Glycemic control and clinical outcomes in US patients with COVID-19: data from the National COVID Cohort Collaborative (N3C) database

R Wong, M Hall, R Vaddavalli, A Anand, N Arora… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE The purpose of the study is to evaluate the relationship between HbA1c and
severity of coronavirus disease 2019 (COVID-19) outcomes in patients with type 2 diabetes …

Association between SGLT2 inhibitor treatment and diabetic ketoacidosis and mortality in people with type 2 diabetes admitted to hospital with COVID-19

K Khunti, Y Ruan, J Davies, BCT Field, S Harris… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE To determine the association between prescription of SGLT2 inhibitors
(SGLT2is) and diabetic ketoacidosis (DKA) incidence or mortality in people with type 2 …

[HTML][HTML] Контроль гликемии и выбор антигипергликемической терапии у пациентов с сахарным диабетом 2 типа и COVID-19: консенсусное решение совета …

ИИ Дедов, НГ Мокрышева, МВ Шестакова… - Сахарный …, 2022 - cyberleninka.ru
С декабря 2019 г. в мире активно распространяется опасное вирусное заболевание-
COVID-19, вызванное новым РНК-коронавирусом SARS-COV-2. Основным …